Joshua A Jacobs

US Patent:

7363193, Apr 22, 2008

Filed:

Apr 16, 2002

Appl. No.:

10/123233

Inventors:

John M. Jacobs - Hilton Head SC, US
Joshua D. Jacobs - Chicago IL, US
Colleen M. Jardine - Collingwood, ONT, CA

International Classification:

G06F 11/30

US Classification:

702182, 709224, 705 40, 705 1, 703 2

Abstract:

A safety management system includes a processor and memory in which a safety database is maintained. The safety management system receives safety data from one or more portable devices and/or computers, and the system stores this safety data in the database. When a safety incident occurs, such as an accident, the type of incident is recorded and additional information about the incident is recorded in the database. This information then is used to generate a model of the rate of safety incidents. This model is then used to forecast future safety incidence rates for planning and budgeting purposes.

US Patent:

20200181253, Jun 11, 2020

Filed:

Dec 11, 2018

Appl. No.:

16/216159

Inventors:

- Chicago IL, US
Lauryn A. SAMELKO - Chicago IL, US
Joshua J. JACOBS - Wilmette IL, US

International Classification:

C07K 16/24
A61P 37/06
A61K 45/06

Abstract:

Described herein is a method for treating or prophylaxis of adverse immune reaction to metal debris, metal induced delayed type hypersensitivity (DTH), or inflammatory osteolysis by attenuating the inflammatory response. In one aspect, the method involves inhibiting the nucleotide-binding domain (NOD)-like receptor protein 3 (NLRP3) inflammasome/caspase-1 pathway or neutralizing or blocking the activity of interleukin 17 (IL-17), IL-17 receptor (IL-17R), IL-1R, IL-1(3, IL-18, IL-21, IL-23 with anti-IL-17, anti-IL-17A, anti-IL-17F, anti-IL-17A/F, anti-IL-1, anti-IL-1β, anti-IL-18, anti-IL-21, anti-IL-23, anti-IL-1R, soluble IL-17 receptors, soluble IL-1 receptors, soluble IL-18 receptors, soluble IL-21 receptors, IL-17 receptor inhibitors, IL-1 receptor inhibitors, IL-18 receptor inhibitors, IL-21 receptor inhibitors, IL-23 receptor inhibitors, blocking agents, inflammasome inhibitors, or combinations thereof.

US Patent:

20190285649, Sep 19, 2019

Filed:

Mar 19, 2019

Appl. No.:

16/357578

Inventors:

- Chicago IL, US
Dale Richman Sumner - Chicago IL, US
Joshua J. Jacobs - Chicago IL, US

Assignee:

Rush University Medical Center - Chicago IL

International Classification:

G01N 33/68

Abstract:

Methods and kits for measuring a panel of biomarkers in a subject suspected of being at risk for peri-implant osteolysis are provided. The method includes obtaining a biological sample from the subject; and measuring a level of at least two biomarkers in a biomarker panel in the sample, wherein the biomarker panel comprises α-crosslaps (α-CTX), β-crosslaps (β-CTX), Interleukin-6 (IL-6), Interleukin-8 (IL-8), osteoprotegrin (OPG), deoxypyridinoline (DPD), and cross-linked N-telopeptides (NTX).